The Senate Finance Committee held on Tuesday the third in a series of hearings on drug pricing in America, which focused on the role of pharmacy benefit managers. 
  
"PBMs negotiate with the drug companies, as well as pharmacies, to arrive at a price for a drug and its ultimate cost," said Committee Chairman Chuck Grassley, R-Iowa. "This system of private entities negotiating is what I envisioned as an author of the Part D program. I still believe this is absolutely the right approach. ... However, it's our duty to understand how the system is working today and what we can do to improve it." 
  
Ranking Member Ron Wyden, D-Ore., said, "PBMs are supposed to be negotiators who get better deals on prescription drugs for patients. What they are is middlemen who've raked in profits while drug prices have shot into the stratosphere. And as most people will tell you, there are already too many middlemen taking a cut in the American health care system." 
  
Testifying at the hearing were Steve Miller, M.D., executive vice president and chief clinical officer of Cigna; Derica Rice, executive vice president of CVS Health and president of CVS Caremark; William Fleming, segment president, health care services at Humana; John Prince, CEO of OptumRx; and Mike Kolar, interim president and CEO at Prime Therapeutics.

Related News Articles

Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…